Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
29.29 USD -0.41% Intraday chart for Pacira BioSciences, Inc. -5.58% -13.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating MT
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue MT
Transcript : Pacira BioSciences, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024 CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024 CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85 MT
North American Morning Briefing : Fed's Preferred -2- DJ
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy CI
Pacira BioSciences Awarded Group Purchasing Agreement with Premier MT
Pacira BioSciences Receives Brand Pharmaceuticals Agreement With Premier, Inc CI
Transcript : Pacira BioSciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus MT
Pacira Reports Unaudited Preliminary Sales Results for the Fourth Quarter and Full-Year Ended December 31, 2023 CI
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating MT
Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024 CI
Pacira Biosciences, Inc. Appoints Frank D. Lee as Member of the Board, Effective January 2, 2024 CI
Pacira BioSciences Names Frank D. Lee CEO, Board Member MT
Raymond James Initiates Pacira BioSciences With Outperform Rating, Price Target is $42 MT
Chart Pacira BioSciences, Inc.
More charts
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain, spasticity and stellate ganglion block. The Company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
29.29 USD
Average target price
45.73 USD
Spread / Average Target
+56.12%
Consensus
  1. Stock
  2. Equities
  3. Stock Pacira BioSciences, Inc. - Nasdaq
  4. News Pacira BioSciences, Inc.
  5. Pacira BioSciences Sees Fiscal 2022 Earnings, Revenue Trailing Analyst Estimates; Shares Slipping in Late Trade